Press


For Immediate Release: 


AURORA, CO – May 1, 2017 — Galaxy Ophthalmics, LLC today announced it has entered into an exclusive global license agreement with i2 Pharmaceuticals, Inc. for rights to i2 Pharma’s technologies in the field of Ophthalmology. Details of the agreement are undisclosed, with i2 Pharma receiving controlling interest in the Company and future royalties on product sales in exchange for the exclusive license. Together, Galaxy Ophthalmics and i2 Pharmaceuticals are initially developing therapies for Age-Related Macular Degeneration (AMD), with other Ophthalmic diseases slated to follow.

“i2 Pharma’s underlying drug discovery and development technologies represent a generational leap beyond the current processes in the pharmaceutical industry” shares Fred Mitchell, Galaxy’s CEO. “We are privileged to be a part of this effort to dramatically improve on the therapeutic options for patients at risk from AMD.”

About Galaxy Ophthalmics, LLC
Galaxy Ophthalmics is an early stage company developing products addressing Age-related Macular Degeneration and Glaucoma, the leading causes of blindness.

Contact
info@galaxyophthalmics.com


About i2 Pharmaceuticals, Inc.
i2 Pharmaceuticals is a biopharmaceutical company focused on next generation discovery and development of therapeutics, with a focus on personalized cancer treatment. It is unique in that it generates its pipeline of product candidates from its proprietary suite of transformative technologies including small molecules, antibodies and nucleic acid based therapeutics. 

Contact
info@i2pharma.com


For Immediate Release: 


AURORA, CO – May 1, 2017 — Galaxy Ophthalmics, LLC today announced it has appointed Dr. Bruce Eaton to its Board of Directors. A 35-year veteran of the pharmaceutical and diagnostics industry, Dr. Eaton brings a pool of knowledge that is both deep and broad to the Galaxy Ophthalmics team. His appointment is effective immediately.

“We are fortunate to have Dr. Eaton join with us in providing relief to people suffering from Ophthalmic Diseases. He brings a wealth of proven business and technology leadership experience,” states Fred Mitchell, CEO of Galaxy. “We are extremely pleased that he is joining Galaxy’s board.”

About Galaxy Ophthalmics, LLC
Galaxy Ophthalmics is an early stage company developing products addressing Age-Related Macular Degeneration and Glaucoma, the leading causes of blindness.

Contact
info@galaxyophthalmics.com



For Immediate Release: 

AURORA, CO – May 1, 2017 — Galaxy Ophthalmics, LLC today announced it has appointed Dr. Ramanath Bhandari to its Scientific Advisory Board. Dr. Bhandari is a Board Certified Ophthalmologist and is a Partner at The Eye Institute at the Springfield Clinic in Springfield, IL. Active in patient care and in collaborations with industry, he is in touch with current standards of care and direction of the future. His appointment is effective immediately.

“Dr. Bhandari brings experience and clear patient focus to our team,” states Fred Mitchell, CEO of Galaxy. “We are thrilled that he is joining our board.”

About Galaxy Ophthalmics, LLC
Galaxy Ophthalmics is an early stage company developing products addressing Age-Related Macular Degeneration and Glaucoma, the leading causes of blindness.

Contact
info@galaxyophthalmics.com